Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.
She previously served as interim regulatory leader, overseeing compliance, submissions, and risk mitigation, and brings over 35 years of healthcare and medical technology experience across regulatory, quality, operations, clinical, and laboratory roles.
Details
News Market Reaction – IART
On Jul 2, the day this news came out, IART closed 0.89% above the previous close.
Data tracked by StockTitan Argus for the Jul 2 session.
Key Figures
- Industry experience
- more than 35 years
- Healthcare and medical technology experience for new chief regulatory officer
- Equity plan increase
- 3,550,000 shares
- Additional common shares approved for equity awards at 2026 Annual Meeting
- Paradigm ownership
- 4,012,698 shares (5.16%)
- Schedule 13G passive stake as of 03/31/2026
- Shares issued
- 77,886,634 shares
- Common stock issued as of December 31, 2025
- Treasury stock
- 14,398,724 shares
- Common shares designated as treasury stock as of December 31, 2025
- Reference share price
- $11.59
- IART Nasdaq closing price on February 25, 2026 cited in S-3ASR
- McBreen RSU grant
- 31,909 RSUs
- Equity award to EVP & Chief Commercial Officer on Form 4
- Essig option grant
- 705,468 options at $15.67
- Non-qualified stock options granted to President and CEO
Historical Context
-
New senior commercial leadership roles announced to support long-term growth.
-
Company presentation scheduled at the 2026 Truist Securities MedTech Conference.
-
CFO presentation announced for the 2026 Jefferies Global Healthcare Conference.
-
CFO scheduled to present at the BofA Securities 2026 Health Care Conference.
-
Stuart Essig appointed president and CEO in a permanent leadership transition.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
regulatory affairs regulatory
regulatory compliance regulatory
clinical laboratory scientist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Kirlew will lead Integra’s global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution.
PRINCETON, N.J., July 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a global leader in medical technology, today announced the appointment of Topaz Kirlew, DBA, MBA, as corporate vice president and chief regulatory officer. Kirlew will lead Integra's global regulatory affairs organization and oversee regulatory strategy, compliance, submissions, and transformation initiatives worldwide.
Kirlew served as the interim regulatory leader for the company over the past several months, leading the global regulatory organization during an important period for the company. In her interim capacity, she provided oversight of regulatory compliance, managed active submissions, and led risk mitigation efforts across the organization.
"Topaz brings deep regulatory experience, sound judgment, and a practical approach to helping the business move forward the right way," said Stuart Essig, chairman and chief executive officer of Integra LifeSciences. "She has earned the confidence of the leadership team, and I am pleased to have her in this role as we continue to strengthen our regulatory capabilities and advance our mission of restoring patients' lives."
Since joining Integra in 2021, Kirlew has played a key role in building the company's regulatory capabilities and advancing key business priorities. She brings more than 35 years of healthcare and medical technology industry experience spanning regulatory affairs, quality, operations, and clinical functions.
Prior to joining Integra, Kirlew held positions of increasing responsibility at several healthcare and medical technology organizations, including Danaher Corporation, Apyx Medical, Bio-Tissue, and the University of Miami's Diabetes Research Institute. She began her career as a clinical laboratory scientist, serving at leading healthcare institutions including the National Institutes of Health, Georgetown University Hospital, and the University of Maryland Medical Center.
Kirlew earned a bachelor’s degree in clinical laboratory science from Florida International University and holds a master's degree and a doctorate in business administration from Nova Southeastern University's School of Business and Entrepreneurship.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard technologies is trusted by healthcare professionals to deliver transformative care. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
chris.ward@integralife.com
Media Contact:
Laurene Isip
(609) 208-8121
laurene.isip@integralife.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a23fae4-98d6-4910-9b3a-5172804e1e1c
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.